GNMK News and Press, GenMark Diagnostics Inc. From 02/10/20

GenMark Diagnostics (NASDAQ: GNMK ) says Hany Massarany has stepped down as President and CEO and as a board member, effective immediately. More news on: GenMark Diagnostics, Inc., Healthcare stocks news, Read more ...

CARLSBAD, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Monday, March 2, 2020. Management will hold a conference call to review the comp...

CARLSBAD, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that Scott Mendel, Chief Operating Officer, has been appointed Interim President and Chief Executive...

It’s at least a little ghoulish to read the reports of the coronavirus outbreak in China and think “how can I profit from this?”, but the reality is that outbreaks like these can be stock drivers. While I think the financial impact to GenMark Diagnostics ( GNMK ) will be...

The following slide deck was published by GenMark Diagnostics, Inc. in conjunction with this Read more ...

GenMark Diagnostics ( GNMK -3.7% )  provides preliminary operational and financial results for FY 2019. More news on: GenMark Diagnostics, Inc., Healthcare stocks news, Read more ...

CARLSBAD, Calif., Jan. 13, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2019. Financial High...

CARLSBAD, Calif., Dec. 30, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming J.P. Morgan Healthcare conference in San Franci...

I can understand why investors may be leery of GenMark ( GNMK ). Although management has done a much better job of late in hitting its own targets, that has certainly not always been the case. Worse, they’re a later entrant into the multiplex molecular diagnostics field, and both bio...

AdaptHealth (NASDAQ: AHCO ) initiated with Outperform rating and $13 (30% upside) price target at SVB Leerink. More news on: AdaptHealth Corp., CryoLife, Inc., Acadia Healthcare Company, Inc., Healthcare stocks news, Stocks on the move, , Read more ...